

Impact of Huntington’s Disease on Driving: A Review of Driving Simulator Measures and Association With Clinical Outcomes Assessments

Emma Hawe,¹ Colleen Castro,² Jason Johannesen,³ Jose Marcano Belisario,¹ Margaret Mordin,² Ruta Sawant,³ Jennifer Petrillo³

¹RTI Health Solutions, Manchester, United Kingdom; ²RTI Health Solutions, Research Triangle Park, NC, United States; ³Sage Therapeutics Inc., Cambridge, MA, United States

Background

- Huntington’s disease (HD) is a genetic, neurodegenerative disease characterized by motor, behavioral, and cognitive symptoms.¹
- Cognitive decline can begin many years prior to motor manifestation, first noticed in executive functions involving multitasking, organizing thoughts, planning, and decision making.² As a result, patients may withdraw from more challenging activities during otherwise productive and independent phases of life.³
- One of the earliest concerns reported by patients with HD is the impact on driving abilities, particularly driving safety.^{4,5}
- Driving is important for employment, general family responsibilities, social activities, and for the feeling of independence.⁶
- Measuring driving outcomes as a proxy for clinically relevant outcomes that require cognitive capabilities can be one way to closely track cognitive changes that occur in premanifest and early manifest HD.
- Understanding the relationship of meaningful driving outcomes and clinical outcomes assessments (COAs) frequently used in HD to comprehend cognitive impairment changes can be a useful way to build the clinical meaningfulness of COAs.

Objective

- To summarize literature on the impact of HD on driving (as measured by simulator measures) and the relationship between clinical outcomes assessments (COAs) and driving simulator measures in an HD population (Figure 1).

Methods

Design
Targeted literature review in PubMed from 2011-2021; English language only; search terms for driving, simulators, and cognitive assessments
Population
Patients with HD
Driving outcomes
Accidents, attention/reaction, distance control, general errors, infractions, lane position, and speed
Analyses
- Driving outcomes in HD vs. control: standardized mean differences (Hedge’s g method) - Driving outcomes and COAs in HD: correlation coefficients with confidence intervals calculated with R metacor using reported or estimated sample size

Results

- 378 records were identified in PubMed, of which 4 (corresponding to 3 studies) were included in the review (Table 1).
- Studies were most commonly excluded due to population and outcomes of interest.
- Simulation measures included: number of accidents, response and reaction time (e.g., time to switch lanes prior to lane closure), distance to preceding cars, errors, number of traffic tickets, vehicle control measured by deviations in lane positioning, and driving speed measured by the mean speed and standard deviation in speed.
- Most consistently used COAs: Stroop test, Hopkins Verbal Learning Test, Wisconsin Card Sorting Test, Trail Making Test, Wechsler Adult Intelligence Scale–Revised (WAIS-R), and clinical rating scales.
- Compared with controls, patients with HD showed an increased frequency of accidents, tickets, and general errors (Figure 2).
- The strength of the correlations between COAs and driving measures in patients with HD ranged from low (0.04) to high (0.85) and varied across driving measure categories and COA measures (Figure 3).
- The Trail Making Test, commonly used in clinical evaluation of fitness to drive, was moderately correlated with speed (0.43) and lane position (0.49).

Table 1. Summary of Included Studies

Reference, Objective	Population (n)	Driving Outcomes	COAs
Devos et al. (2012) ⁷ OBJECTIVE: To identify the most accurate clinical predictors of fitness to drive in HD	• Manifest HD (30) • Healthy controls (30)	Fitness to drive (pass/fail): Binocular visual acuity, kinetic vision, contrast sensitivity, figure of Rey, UFOV, 4-choice reaction times, visual scanning, DA, Test for Attentional Performance; accident; traffic tickets; DA (responding to symbols presented in the periphery of the screen)	MMSE, TMT-A and TMT-B, Stroop Test, SDMT, UHDRS-TFC motor and behavioral scores, LVFT
Jacobs et al. (2018) ⁸ OBJECTIVE: to identify differences in driving performance between HD gene carriers and healthy individuals in simulated urban and motorway environments	• Premanifest HD (28) • Manifest HD (30) • Healthy controls (29)	SDLP, mean speed, SD of mean speed, distance to preceding car in meters, reaction time to lane closures	UHDRS-TFC scores, finger tapping, saccadic inaccuracy, smooth pursuit, body sway, TMT-B, Stroop test, SDMT, adaptive tracking, SART, PBA-s, FrSBe, HADS-SIS
Jacobs et al. (2019) ⁹ OBJECTIVE: To investigate whether cognitive, motor, or psychiatric symptoms can predict driving performance in HD gene carriers using a simulator situation			
Rebok et al. (1995) ⁹ OBJECTIVE: To assess the influence of the neurological and cognitive impairments of HD on automobile driving	• HD: Driving (53) • HD: Not driving (20) • Healthy controls (22)	Errors (maintaining appropriate speed, use of turn signals, force applied to brake, use of accelerator, position of steering wheel); Evasive Action Skill task (situations in which appropriate action must be taken to avoid a collision); responding to cues presented on the screen (cue-recognition task)	• MMSE, TMT-A and TMT-B, Stroop test, HD-ADL, QNE, WAIS-R: Vocabulary and block design, WMS-R: logical memory and visual reproduction, VMI, FAS, BTA, HVLIT, WCST, Motor-Free Visual Perception Test, Spatial Recognition Span Test, Reaction time tasks

BTA = brief test of attention; COA = clinical outcomes assessment; DA = divided attention; FAS = Controlled Oral Word Association Test; FrSBe = Frontal System Behavior Scale; HADS = Hospital Anxiety Depression Scale; HD-ADL = Huntington’s disease activity of daily living; HVLIT = Hopkins Verbal Learning Test; LVFT = Letter Verbal Fluency Test; MMSE = Mini-Mental State Examination; PBA-s = Problem Behavior Assessment–Short; QNE = quantitative neurological examination; SART = sustained attention to response task; SD = standard deviation; SDLP = standard deviation of the lateral position; SDMT = Symbol Digit Modalities Test; SIS = Smith Irritability Scale; TFC = total functional capacity; TMT-A = Trail Making Test Part A; TMT-B = Trail Making Test Part B; UFOV = Useful Field of View; UHDRS = Unified Huntington’s Disease Rating Scale; VMI = visual-motor integration; WAIS-R = Wechsler Adult Intelligence Scale–Revised; WCST = Wisconsin Card Sorting Test; WMS-R = Wechsler Memory Scale–Revised.
Note: Two publications regarding one study.^{8,9}

Figure 1. Example of (A) Driving Simulator, (B) Scenario Displayed on Middle Screen, and (C) Sample COA: Trail Making Test






Figure 2. Descriptive Forest Plot of Differences in Simulated Driving Performance Between Patients With HD and Controls



Discussion

- Driving outcomes related to accidents, error, tickets, or reaction/attention better differentiated HD from healthy controls than outcomes related to speed, distance control, or lane positioning. This could indicate impairment in executive functioning domains like processing speed, working memory, and multitasking.
- Driving outcomes correlated with cognitive performance in domains relevant to HD pathology, such as visuospatial ability and psychomotor speed (WAIS-R), learning and memory (HVLIT), and attention (BTA), suggesting that decline in these abilities may contribute to driving challenges.

Figure 3. Descriptive Forest Plot of the Correlation Between Simulated Driving Outcomes and Clinical Outcomes Assessment in Patients With HD



Conclusions

Simulated driving performance shows promise as a potential outcome measure to assess the functional impact of HD on day-to-day activities. This can further help in establishing clinical meaningfulness of cognitive changes in HD and evaluate treatment effects for therapeutic development in HD.

References

- Huntington’s Together. <https://www.huntingtonsdiseasehcp.com/about-huntingtons-disease.html>. Accessed 27 July 2021.
- Ross CA. *Mov Disord*. 2014;29(11):1351-1358.
- Beglinger LJ, et al. *Mov Disord*. 2012 Aug;27(9):1146-52.
- Williams JK, et al. *PLoS Curr*. 2011 Aug 11;3:RRN1254.
- Beglinger LJ, et al. *Psychiatry Res*. 2010 Jul 30;178(2):414-8.
- Jacobs M, et al. *J Neurol*. 2017 Aug;264(8):1678-96.
- Devos H, et al. *Neurology*. 2012;79:1975-82.
- Jacobs M, et al. *Traffic Inj Prev*. 2018;19(7):706-14.
- Jacobs M, et al. *Parkinsonism Relat Disord*. 2019 Mar;60:64-9.
- Rebok GW, et al. *Mov Disord*. 1995;10:778-87.

Contact Information

Margaret Mordin, MS
Executive Director
RTI Health Solutions
Phone: 703.483.9009
Email: mmordin@rti.org